NL300962I1 - patiromer sorbitex calcium - Google Patents

patiromer sorbitex calcium

Info

Publication number
NL300962I1
NL300962I1 NL300962C NL300962C NL300962I1 NL 300962 I1 NL300962 I1 NL 300962I1 NL 300962 C NL300962 C NL 300962C NL 300962 C NL300962 C NL 300962C NL 300962 I1 NL300962 I1 NL 300962I1
Authority
NL
Netherlands
Prior art keywords
patiromer
sorbitex
calcium
sorbitex calcium
patiromer sorbitex
Prior art date
Application number
NL300962C
Other languages
English (en)
Other versions
NL300962I2 (nl
Original Assignee
Vifor Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300962(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ltd filed Critical Vifor Int Ltd
Publication of NL300962I1 publication Critical patent/NL300962I1/nl
Publication of NL300962I2 publication Critical patent/NL300962I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
NL300962C 2008-08-22 2018-12-14 patiromer sorbitex calcium NL300962I2 (nl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US9109708P 2008-08-22 2008-08-22
US9111008P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US16589409P 2009-04-01 2009-04-01
US16589909P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
PCT/US2009/054706 WO2010022383A2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP09748557.7A EP2365988B2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (2)

Publication Number Publication Date
NL300962I1 true NL300962I1 (nl) 2018-12-28
NL300962I2 NL300962I2 (nl) 2020-06-02

Family

ID=41707686

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300962C NL300962I2 (nl) 2008-08-22 2018-12-14 patiromer sorbitex calcium

Country Status (27)

Country Link
US (4) US20110236340A1 (nl)
EP (4) EP3431094B1 (nl)
JP (7) JP5756403B2 (nl)
KR (5) KR101825113B1 (nl)
CN (2) CN102202670B (nl)
AU (1) AU2009282721B2 (nl)
BR (1) BRPI0917853C1 (nl)
CA (1) CA2735058C (nl)
CY (3) CY2018002I1 (nl)
DE (1) DE112009002063T5 (nl)
DK (3) DK3431094T3 (nl)
ES (3) ES2545887T5 (nl)
FI (1) FI3431094T3 (nl)
GB (4) GB2475657B (nl)
HK (1) HK1184675A1 (nl)
HR (3) HRP20230091T1 (nl)
HU (3) HUE025934T2 (nl)
LT (4) LT2957286T (nl)
LU (1) LUC00094I2 (nl)
MX (2) MX364398B (nl)
NL (1) NL300962I2 (nl)
NO (2) NO2018004I1 (nl)
PL (3) PL2957286T3 (nl)
PT (3) PT3431094T (nl)
SI (2) SI2957286T1 (nl)
SM (1) SMT201500207T1 (nl)
WO (1) WO2010022383A2 (nl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
GB2475657B (en) 2008-08-22 2013-05-29 Relypsa Inc Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2011119422A1 (en) * 2010-03-20 2011-09-29 Relypsa, Inc. Continuous process for preparing polyfluoroacrylate particles
EP3246287A1 (en) 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN110028603A (zh) * 2011-06-27 2019-07-19 瑞立普萨公司 用于将聚合酯转化为聚合酸的方法
EP3653597A1 (en) 2011-06-27 2020-05-20 Relypsa, Inc. Fluorination of acrylate esters and derivatives
IN2015DN01369A (nl) * 2012-07-19 2015-07-03 Relypsa Inc
KR101694080B1 (ko) * 2012-08-09 2017-01-06 데페익스 피네 케미칼스 오스트리아 게엠베하 운트 코 카게 중합체 물질의 건조 방법
KR20150088243A (ko) * 2012-10-08 2015-07-31 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
AU2014248081B2 (en) 2013-04-05 2019-02-28 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
MX2017007603A (es) * 2014-12-23 2017-10-19 Ardelyx Inc Composiciones y metodos para tratar hiperpotasemia.
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
BR112021017791A2 (pt) * 2019-03-13 2022-02-01 Astrazeneca Ab Agentes de ligação ao potássio para uso em pacientes em hemodiálise
US20230002306A1 (en) * 2019-11-14 2023-01-05 Vifor (International) Ltd. One step synthesis for alkyl 2-fluoroacrylates
WO2023035274A1 (en) * 2021-09-13 2023-03-16 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. Polymer medicament for treating hyperkalemia and preparation method thereof
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (nl) 1967-01-30
FR2171934B1 (nl) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
EP0565086B1 (en) 1992-04-10 1996-12-27 Mitsubishi Chemical Corporation Method for producing a spherical acrylonitrile crosslinked copolymer
US5633344A (en) * 1992-08-20 1997-05-27 E. I. Du Pont De Nemours & Company Crosslinked polymeric ammonium salts
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
DE69316933T2 (de) * 1993-11-25 1998-05-28 Salternate B.V., Rotterdam Teilchen zum binden monovalenten kationen und ihre verwendung
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
AU780873B2 (en) * 2000-01-14 2005-04-21 Otsuka Pharmaceutical Factory, Inc. Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
DE60135760D1 (de) * 2000-08-01 2008-10-23 Oryza Oil & Fat Chem Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess
WO2002040039A2 (en) * 2000-11-20 2002-05-23 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
WO2004076021A1 (en) * 2003-02-25 2004-09-10 Finnfeeds Finland Oy A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
KR101228233B1 (ko) * 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
BRPI0616604A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica
GB2446076B (en) * 2005-09-30 2010-11-24 Ilypsa Inc Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CA2697803A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
WO2010022382A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
GB2475657B (en) 2008-08-22 2013-05-29 Relypsa Inc Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Also Published As

Publication number Publication date
KR20200029614A (ko) 2020-03-18
HUE061320T2 (hu) 2023-06-28
JP2012500806A (ja) 2012-01-12
MX2011001893A (es) 2011-09-27
SMT201500207T1 (it) 2015-10-30
PT3431094T (pt) 2023-03-03
WO2010022383A2 (en) 2010-02-25
KR101825113B1 (ko) 2018-02-02
GB2495426A (en) 2013-04-10
CY1120930T1 (el) 2020-05-29
SI2957286T1 (sl) 2018-12-31
JP2020172537A (ja) 2020-10-22
GB201222749D0 (en) 2013-01-30
JP2019065030A (ja) 2019-04-25
PL2957286T3 (pl) 2019-03-29
ES2545887T5 (es) 2020-02-17
US20110236340A1 (en) 2011-09-29
CN102202670B (zh) 2014-04-30
BRPI0917853C1 (pt) 2021-05-25
GB2475657B (en) 2013-05-29
HRP20181961T1 (hr) 2019-02-08
JP6232468B2 (ja) 2017-11-15
LTC2957286I2 (lt) 2019-11-25
PT2957286T (pt) 2018-11-30
GB2495427B (en) 2013-08-07
SI3431094T1 (sl) 2023-04-28
GB2495427A (en) 2013-04-10
US20220000906A1 (en) 2022-01-06
CN103919792A (zh) 2014-07-16
AU2009282721B2 (en) 2015-10-29
PL2365988T5 (pl) 2019-11-29
PL3431094T3 (pl) 2023-04-24
FI3431094T3 (fi) 2023-03-20
EP2365988B1 (en) 2015-07-22
HUE025934T2 (en) 2016-05-30
HK1184675A1 (en) 2014-01-30
GB201222752D0 (en) 2013-01-30
BRPI0917853B1 (pt) 2020-04-07
KR20110063647A (ko) 2011-06-13
KR102178208B1 (ko) 2020-11-12
AU2009282721A1 (en) 2010-02-25
JP2014144977A (ja) 2014-08-14
JP6633583B2 (ja) 2020-01-22
JP5756403B2 (ja) 2015-07-29
JP5883471B2 (ja) 2016-03-15
KR20200128600A (ko) 2020-11-13
US20200289550A1 (en) 2020-09-17
NO2018041I1 (nl) 2018-12-14
DK2365988T4 (da) 2019-10-07
DK2957286T3 (en) 2018-12-17
LUC00094I2 (nl) 2020-01-23
LT3431094T (lt) 2023-02-27
LTPA2018016I1 (lt) 2019-01-10
ES2545887T3 (es) 2015-09-16
KR102300471B1 (ko) 2021-09-30
US20170165292A1 (en) 2017-06-15
CY2018002I1 (el) 2019-07-10
ES2939021T3 (es) 2023-04-18
CA2735058A1 (en) 2010-02-25
KR102150184B1 (ko) 2020-08-31
BRPI0917853A2 (pt) 2015-11-24
DE112009002063T5 (de) 2012-01-12
PT2365988E (pt) 2015-10-22
CY2019002I1 (el) 2020-05-29
JP2014144978A (ja) 2014-08-14
KR101928973B1 (ko) 2018-12-13
LUC00094I1 (nl) 2018-12-19
CA2735058C (en) 2021-01-26
EP2957286B1 (en) 2018-11-21
EP2957286A1 (en) 2015-12-23
EP2365988A2 (en) 2011-09-21
EP4201408A1 (en) 2023-06-28
JP2017218454A (ja) 2017-12-14
KR20180133561A (ko) 2018-12-14
KR20180014845A (ko) 2018-02-09
EP3431094A1 (en) 2019-01-23
NL300962I2 (nl) 2020-06-02
GB2475657A (en) 2011-05-25
DK3431094T3 (da) 2023-02-20
ES2699494T3 (es) 2019-02-11
MX364398B (es) 2019-04-24
WO2010022383A3 (en) 2010-09-23
HRP20150955T1 (hr) 2015-10-09
LT2957286T (lt) 2018-12-10
GB201104561D0 (en) 2011-05-04
GB2495428A (en) 2013-04-10
LTPA2018004I1 (lt) 2018-02-12
CN102202670A (zh) 2011-09-28
HRP20230091T1 (hr) 2023-03-17
GB201222750D0 (en) 2013-01-30
DK2365988T3 (en) 2015-10-26
HUS1900003I1 (hu) 2019-02-28
NO2018004I1 (no) 2018-01-17
JP6890116B2 (ja) 2021-06-18
CY2019002I2 (el) 2020-05-29
PL2365988T3 (pl) 2015-12-31
EP2365988B2 (en) 2019-07-03
CN103919792B (zh) 2018-03-09
JP2016145256A (ja) 2016-08-12
BRPI0917853B8 (pt) 2020-04-22
EP3431094B1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
NL300962I1 (nl) patiromer sorbitex calcium
NO2018006I1 (no) Atezolizumab
DK2370462T3 (da) Glucagon-analoger
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
FIC20240018I1 (fi) Vamoroloni
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2342454T3 (da) Vindkraftanlæg
DK2379557T3 (da) Aminopyrazol-forbindelse
DE602008003970D1 (de) Strahlstromkalibriersystem
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0907522A2 (pt) biarlamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse